503071-67-8Relevant articles and documents
Convergent synthesis of 2,3-bisarylpyrazolones through cyclization of bisacylated pyrazolidines and hydrazines
Brugel, Todd A.,Hudlicky, Tomas,Clark, Michael P.,Golebiowski, Adam,Sabat, Mark,Endoma, Mary Ann A.,Bui, Vu,Adams, David,Laufersweiler, Matthew J.,Maier, Jennifer A.,Bookland, Roger G.,De, Biswanath
, p. 3195 - 3198 (2007/10/03)
Cyclization of various bisacylated hydrazines and pyrazolidines using DBU or sodium hydride leads to the formation of various mono-, bi- and tricyclic pyrazolone scaffolds in 41-98% yield. The convergent nature by which the precyclization intermediates are constructed allows for rapid derivatization about the pyrazolone core.
The development of monocyclic pyrazolone based cytokine synthesis inhibitors
Golebiowski, Adam,Townes, Jennifer A.,Laufersweiler, Matthew J.,Brugel, Todd A.,Clark, Michael P.,Clark, Cynthia M.,Djung, Jane F.,Laughlin, Steven K.,Sabat, Mark P.,Bookland, Roger G.,VanRens, John C.,De, Biswanath,Hsieh, Lily C.,Janusz, Michael J.,Walter, Richard L.,Webster, Mark E.,Mekel, Marlene J.
, p. 2285 - 2289 (2007/10/03)
4-Aryl-5-pyrimidyl based cytokine synthesis inhibitors that contain a novel monocyclic, pyrazolone heterocyclic core are described. Many of these inhibitors showed low nanomolar activity against LPS-induced TNF-α production. One of the compounds (6e) was found to be efficacious in the rat iodoacetate (RIA) in vivo model of osteoarthritis. The X-ray crystal structure of a pyrazolone inhibitor cocrystallized with mutated p38 (mp38) is presented.
The development of new bicyclic pyrazole-based cytokine synthesis inhibitors
Townes, Jennifer A.,Golebiowski, Adam,Clark, Michael P.,Laufersweiler, Matthew J.,Brugel, Todd A.,Sabat, Mark,Bookland, Roger G.,Laughlin, Steve K.,VanRens, John C.,De, Biswanath,Hsieh, Lily C.,Xu, Susan C.,Janusz, Michael J.,Walter, Richard L.
, p. 4945 - 4948 (2007/10/03)
4-Aryl-5-pyrimidyl-based cytokine synthesis inhibitors of TNF-α production, which contain a novel bicyclic pyrazole heterocyclic core, are described. Many of these inhibitors showed low nanomolar activity against LPS-induced TNF-α production in a THP-1 cell-based assay and against human p38α MAP kinase in an isolated enzyme assay. The X-ray crystal structure of a bicyclic pyrazole inhibitor co-crystallized with mutated p38 (mp38) is presented. 4-Aryl-5-pyrimidyl-based cytokine synthesis inhibitors of TNF-α production, which contain a novel bicyclic pyrazole heterocyclic core, are described. Many of these inhibitors showed low nanomolar activity against LPS-induced TNF-α production in a THP-1 cell-based assay and against human p38α MAP kinase in an isolated enzyme assay. The X-ray crystal structure of a bicyclic pyrazole inhibitor co-crystallized with mutated p38 (mp38) is presented.